ARCUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)

Item 5.02    Departure of Directors or Certain Officers; Election of Directors;
             Appointment of Certain Officers; Compensatory Arrangements of
             Certain Officers.

On January 6, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Michael Quigley, Ph.D., to Arcus's Board as a Class III Director. Dr. Quigley is the Senior Vice President of Research Biology at Gilead Sciences, Inc. and is being appointed pursuant to the previously announced Investor Rights Agreement entered into between Arcus and Gilead. The Investor Rights Agreement was entered into in connection with previously announced Option, License and Collaboration Agreement and Common Stock Purchase Agreement entered into between Arcus and Gilead on May 27, 2020.

Dr. Quigley will not receive any compensation for his service as a member of Arcus's Board. Arcus expects to enter into its standard form of indemnification agreement with Dr. Quigley.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses